Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy

Nature Communications

Volumn 8, Issue , 2017, Pages

  Kallert, Sandra M ^a   Darbre, Stephanie ^b   Bonilla, Weldy V ^a   Kreutzfeldt, Mario ^b,c   Page, Nicolas ^b   Müller, Philipp ^a,i   Kreuzaler, Matthias ^a   Lu, Min ^a   Favre, Stephanie ^d   Kreppel, Florian ^e   Löhning, Max ^f,g   Luther, Sanjiv A ^d   Zippelius, Alfred ^a,h   Merkler, Doron ^b,c   Pinschewer, Daniel D ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALARMIN; CD8 ANTIGEN; INTERLEUKIN 33; TUMOR ANTIGEN; VIRUS VECTOR; CANCER VACCINE; IL33 PROTEIN, MOUSE; LIVE VACCINE;

ANTIGEN; BIOENGINEERING; CANCER; CELLS AND CELL COMPONENTS; DISEASE VECTOR; GENE EXPRESSION; PROTEIN; TUMOR; VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOID TISSUE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DBA MOUSE; DRUG SCREENING; DRUG THERAPY; GENE EXPRESSION PROFILING; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MESOCRICETUS; NEOPLASM; PROCEDURES; TUMOR CELL LINE;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

ALARMINS; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; GENE EXPRESSION PROFILING; GENETIC ENGINEERING; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-33; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MESOCRICETUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT; VACCINES, LIVE, UNATTENUATED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020000222     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15327     Document Type: Article

References (70)

1. Andtbacka, R. H., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780-2788 (2015
2. Sharma, P., & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015
3. Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. Prospects for geneengineered T cell immunotherapy for solid cancers. Nat. Med. 22, 26-36 (2016
4. Kantoff, P. W., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010
5. Vansteenkiste, J. F., et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 17, 822-835 (2016
6. Butts, C., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 59-68 (2014
7. Pages, F., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2005
8. Vanneman, M., & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012
9. Zhang, L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003
10. Fuertes Marraco, S. A., et al. Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile upon yellow fever vaccination. Sci. Transl. Med. 7, 282ra248 (2015
11. Bonilla, W. V., et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science 335, 984-989 (2012
12. Querec, T., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413-424 (2006
13. Rosenberg, S. A., Yang, J. C., & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004
14. Gajewski, T. F., Schreiber, H., & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014-1022 (2013
15. Joyce, J. A., & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80 (2015
16. Zamarin, D., et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra232 (2014
17. Zinkernagel, R. M. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 263, 1-5 (2002
18. Webb, H. E., Molomut, N., Padnos, M., & Wetherley-Mein, G. The treatment of 18 cases of malignant disease with an arenavirus. Clin. Oncol. 1, 157-169 (1975
19. Callan, M. F., et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat. Med. 2, 906-911 (1996
20. Kotturi, M. F., et al. Human CD8(+) and CD4(+) T cell memory to lymphocytic choriomeningitis virus infection. J. Virol. 85, 11770-11780 (2011
21. de Lamballerie, X., Fulhorst, C. F., & Charrel, R. N. Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France. Transfusion 47, 172-173 (2007
22. Stephensen, C. B., et al. Prevalence of serum antibodies against lymphocytic choriomeningitis virus in selected populations from two US cities. J. Med. Virol. 38, 27-31 (1992
23. Baumann, C., et al. T-bet- And STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc. Natl Acad. Sci. USA 112, 4056-4061 (2015
24. Reichenbach, D. K., et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 125, 3183-3192 (2015
25. Peine, M., Marek, R. M., & Lohning, M. IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol. 37, 321-333 (2016
26. Flatz, L., et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8(+) T cell immunity. Nat. Med. 16, 339-345 (2010
27. Flatz, L., Bergthaler, A., de la Torre, J. C., & Pinschewer, D. D. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl Acad. Sci. USA 103, 4663-4668 (2006
28. Emonet, S. F., Garidou, L., McGavern, D. B., & de la Torre, J. C. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl Acad. Sci. USA 106, 3473-3478 (2009
29. Hyvarinen, A., Yongabi, F., Makinen, K., Wahlfors, J., & Pellinen, R. Recombination of replicon and helper RNAs and the emergence of propagation-competent vectors upon Sindbis virus vector production. Int. J. Mol. Med. 32, 410-422 (2013
30. Kew, O., et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296, 356-359 (2002
31. Chare, E. R., Gould, E. A., & Holmes, E. C. Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J. Gen. Virol. 84, 2691-2703 (2003
32. Stenglein, M. D., et al. Widespread recombination, reassortment, and transmission of unbalanced compound viral genotypes in natural arenavirus infections. PLoS Pathog. 11, e1004900 (2015
33. Perez, M., & de la Torre, J. C. Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 77, 1184-1194 (2003
34. Suter, M., et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 27, 7442-7450 (2009
35. Popkin, D. L., et al. Expanded potential for recombinant trisegmented lymphocytic choriomeningitis viruses: protein production, antibody production, and in vivo assessment of biological function of genes of interest. J. Virol. 85, 7928-7932 (2011
36. Bonilla, W. V., et al. Effects of promyelocytic leukemia protein on virus-host balance. J. Virol. 76, 3810-3818 (2002
37. Waibler, Z., et al. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J. Virol. 83, 1563-1571 (2009
38. Sommerstein, R., et al. Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog. 11, e1005276 (2015
39. Schirmbeck, R., Reimann, J., Kochanek, S., & Kreppel, F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol. Ther. 16, 1609-1616 (2008
40. Mueller, S. N., et al. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl Acad. Sci. USA 104, 15430-15435 (2007
41. Iwai, Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002
42. Liu, J. Y., et al. CTL- vs Treg lymphocyte-Attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br. J. Cancer 113, 747-755 (2015
43. Liu, J., et al. Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma. Oncotarget 6, 24978-24989 (2015
44. Peng, D., et al. Epigenetic silencing of TH1-Type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249-253 (2015
45. Zhu, J., Huang, X., & Yang, Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 81, 3170-3180 (2007
46. Delaloye, J., et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5, e1000480 (2009
47. Scandella, E., et al. Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat. Immunol. 9, 667-675 (2008
48. Henao-Restrepo, A. M., et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015
49. Spertini, F., et al. Safety of human immunisation with a live-Attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir. Med. 3, 953-962 (2015
50. Hansen, S. G., et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013
51. Flatz, L., et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J. Virol. 86, 7760-7770 (2012
52. Tumeh, P. C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014
53. Spranger, S., Bao, R., & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-Tumour immunity. Nature 523, 231-235 (2015
54. Dunn, G. P., Koebel, C. M., & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836-848 (2006
55. Enria, D. A., & Barrera Oro, J. G. Junin virus vaccines. Curr. Top. Microbiol. Immunol. 263, 239-261 (2002
56. Plyusnin, A., Kukkonen, S. K., Plyusnina, A., Vapalahti, O., & Vaheri, A. Transfection-mediated generation of functionally competent Tula hantavirus with recombinant S RNA segment. EMBO J. 21, 1497-1503 (2002
57. Schumacher, T. N., & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015
58. Darbre, S., et al. The nucleoprotein is required for lymphocytic choriomeningitis virus-based vaccine vector immunogenicity. J. Virol. 89, 11734-11738 (2015
59. Valmori, D., et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 164, 1125-1131 (2000
60. Anton, L. C., et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-Associated antigenic peptides. J. Immunol. 160, 4859-4868 (1998
61. Wortmann, A., et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-Adenovirus antibodies. Mol. Ther. 16, 154-162 (2008
62. Oboki, K., et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl Acad. Sci. USA 107, 18581-18586 (2010
63. Grob, P., et al. Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. J. Virol. 73, 4748-4754 (1999
64. Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E., & McKenzie, A. N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069-1076 (2000
65. Lewandoski, M., Wassarman, K. M., & Martin, G. R. Zp3-cre, a transgenic mouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line. Curr. Biol. 7, 148-151 (1997
66. Quinn, K. M., et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 190, 2720-2735 (2013
67. Doherty, P. C., Biddison, W. E., Bennink, J. R., & Knowles, B. B. Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype. J. Exp. Med. 148, 534-543 (1978
68. Fasnacht, N., et al. Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses. J. Exp. Med. 211, 2265-2279 (2014
69. Zinkernagel, R. M., Leist, T., Hengartner, H., & Althage, A. Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D. J. Exp. Med. 162, 2125-2141 (1985
70. Duan, F., et al. Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. J. Immunol. Methods 382, 224-228 (2012